Vaxil Bio Licenses P-Esbp for Targeted Cancer Therapy from BGN Technologies, the Technology Transfer Company of Ben-Gurion University, Israel

NEXT STORY
Beroni Group Incorporates New PENAO Company with University of New South Wales to Develop the Next Generation Anti-Cancer Drug
PREV STORY
‘Absorbable’ Surgical Sutures to Witness Rapid Adoption, Key Market Players Focus on Competitive Pricing Strategies for Extended Outreach: Fact.MR
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

American Health Council Names Jaime Steinsapir, M.D., PhD, FACP, FACE to Physician Board

NEW YORK, May 23, 2017 (GLOBE NEWSWIRE) -- Dr. Jaime Steinsapir, Endocrinologist at Palm ...

author_avatar
NASDAQ Market News

Benasource Selects Acupath Laboratories to Bring COVID-19 Saliva PCR Assay to Independent Pharmacies Across the Country

author_avatar
NASDAQ Market News

Achaogen Unveils Data Highlighting the Effectiveness of Plazomicin Against MDR Gram-Negative Bacteria at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

-- Evaluation of EPIC Phase 3 data demonstrates sustained clinical cure with plazomicin compared ...

author_avatar
NASDAQ Market News